Jan 4, 2022
MediSieve to Present at Biotech Showcase 2022
MediSieve is presenting virtually at the Biotech Showcase™ 2022 conference.
LONDON – January 04, 2022 – MediSieve, today announced that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation. This year, registered attendees to Biotech Showcase can access MediSieve’s recorded company presentation beginning the week of December 6th – five weeks prior to the actual event. 24x7 on-demand access allows attendees to view presentations at their convenience in case scheduling does not allow viewing during the main event week.
Dr Frodsham will discuss the vast potential of the company's breakthrough therapy, Magnetic Haemofiltration, which will undergo a first-in-man trial in early 2022. This technology is a tool that enables doctors to remove specific things from the bloodstream of patients. It can be used either as a direct treatment, to increase the safety and efficacy of other therapies, or to enable personalised medicine. There are several multi-billion-dollar markets available for it in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. MediSieve could lead the way to a future where these conditions pose far less of a threat to human health than they do right now.
“We are very pleased to be one of the Presenting Companies at the Biotech Showcase this year. MediSieve is at a very exciting stage and we are looking forward to sharing our progress and plans with potential investors at the event,” said George Frodsham, Founder and CEO of MediSieve.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that MediSieve will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
MediSieve will also participate and present in JP Morgan Week, which is the biggest series of events in the industry. In addition to the Biotech Showcase, MediSieve will also participate in IR@JPM Virtual Demo Day. The event will give MediSieve exposure to the industry's top investors. Furthermore, an event hosted by BioMedEng Association will allow the company to connect with major innovators and clinicians within the Biomedical Engineering space. MediSieve is excited to showcase its technology in front of the leading industry players.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: